Kite Pharma
| Company type | Subsidiary | 
|---|---|
| Nasdaq: KITE | |
| Industry | Biopharmaceutical | 
| Founded | 2009 | 
| Founder | Arie Belldegrun and Joshua Kazam | 
| Fate | Acquired by Gilead Sciences | 
| Headquarters | , | 
| Key people | 
 | 
| Products | Cancer immunotherapy | 
| Number of employees | 2,000 | 
| Parent | Gilead Sciences | 
| Website | www.kitepharma.com | 
| Footnotes / references Key People, Founder | |
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.